Investigation and estimation of spectrophotometric values specific and molar absorbances for Losartan Potassium and Valsartan.
Keywords:
Losartan Potassium, Valsartan, spectrophotometry, specific, molar, absorbance
Abstract
The aim of current investigation was the investigation and estimation of spectrophotometric values specific (A1%1cm) and molar (e) absorbances for angiotensin receptor blockers Losartan Potassium and Valsartan. The following experimental results were obtained: for solutions of referense standards Losartan Potassium (lmax = 208 nm) at А > 0.2 (3.10–7 g/ml ¸ 6.75.10–7 g/ml): A1%1cm: 12113 ¸ 12778; e: 558441 ¸ 589064; for Valsartan in 99.8 % еthanol at lmax = 252 nm for А > 0.2 (6.10–6 g/ml ¸ 1.10–5 g/ml): A1%1cm : 774 ¸ 800; e: 33730 ¸ 34840. For Valsartan in mеthanol at lmax = 250 nm for А > 0.2 (3.5.10–6 g/ml ¸ 1.10–5 g/ml): A1%1cm: 480 ¸ 628; e: 20885 ¸ 27368. Specific (A1%1cm) and molar (e) absorbances for А < 0.2 were:
[C] g/ml A1%1cm e
3.5.10–8 ¸ 1.10–7 13107 ¸ 16710 604252 ¸ 770348 Losartan Potassium
5.10–7 ¸ 2.10–6 877 ¸ 880 38221 ¸ 38304 Valsartan (99.8 % еthanol)
1.2.10–6 ¸ 2.5.10–6 574 ¸ 617 24997 ¸ 26875 Valsartan (mеthanol)
Downloads
Download data is not yet available.
References
1. Taylor D.A., Abdel-Rahman A.A. Novel strategies and targets for the management of hypertension. Adv. Pharmacol., 2009; 57: 291-345.
2. Coleman J.J., Butt T.F. Antihypertensive drugs. Side Effects Drugs Annual, 2009; 31(20): 349-370.
3. Ferdinand K.C., Taylor C. The management of hypertension with angiotensin receptor blockers in special populations. Clin. Cornerstone, 2009; 9(Suppl. 3): 5-17.
4. Wachtell K., Lehto M., Gerdts E., Olsen M.H., Hornestam B., Dahlöf B., Ibsen H., Julius S., Kjeldsen S.E., Lindholm L.H., Nieminen M.S., Devereux R.B. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to Atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study. J. Amer. Coll. Cardiol., 2005; 45(5): 712-719.
5. Giles T.D., Oparil S., Silfani T., Walker F. Comparison of ascending doses of Olmesartan medoxomil (O), Losartan potassium (L) and Valsartan (V) in patients (PTS) with essential hypertension (HTN). Amer. J. Hypertens., 2005; 18(5) (Suppl. 1): 59-60.
6. Nixon R.M., Muller E., Lowy A., Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract., 2009; 63(5): 766-775.
7. Kimura Y., Kitagawa K., Oku N., Kajimoto K., Kato H., Tanaka M., Sakaguchi M., Hougaku H., Sakoda S., Hatazawa J. Blood pressure lowering with Valsartan is associated with maintenance of cerebral blood flow and cerebral perfusion reserve in hypertensive patients with cerebral small vessel disease. J. Stroke Cerebrovasc. Disease, 2010; 19(2): 85-91.
8. Delea T.E., Thomas S.K., Moynihan A., Frech F., Oster G. Valsartan versus Lisinopril or Metoprolol to prevent cardiovascular events in patients with hypertension. Amer. J. Hypertens., 2005; 18(5) (Suppl. 1): 55-56.
9. Solomon S.D., Skali H., Anavekar N.S., Bourgoun M., Barvik S., Ghali J.K., Warnica J.W., Khrakovskaya M., Arnold J.M., Schwartz Y., Velazquez E.J., Califf R.M., McMurray J.V., Pfeffer M.A. Changes in ventricular size and function in patients treated with Valsartan, Captopril, or both after myocardial infarction. Circulation, 2005; 111(25): 3411-3419.
10. Janardhanan R., Daley W.L., Naqvi T.Z., Mulvagh S.L., Aurigemma G., Zile M., Arnold J.M.O., Artis E., Purkayastha S., Thomas J.D., Solomon S.D. Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Amer. Heart J., 2006; 152(2): 246-252.
11. Solomon S.D.J., Arnold M.O., Aurigemma G.P., Daley W.L., Verma A. The VALIDD study. Lancet, 2007; 370(9591): 931-932.
12. Momoh H., Idris M.M., Adoum O.A. Evaluation of the antimicrobial and cytotoxic effect of Dendranthema indicum (L Desmoul) leave extract. IJRDO J. Applied Sci., 2017; 3(6): 12-19.
13. Momoh H., Dambata, M.B., Tahir M.T. Phytochemical studies, antimicrobial and antituberculosis evaluation of extracts from the stem bark of Psorospermum senegalense (Spach). IJRDO J. Applied Sci., 2017; 3(6): 3-11.
14. Boakye S., Jonfia-Essien W., Voegborlo B.R, Boadi N.O. Assessment of organochlorine pesticides in cocoa beans from Ashanti and Brong Ahafo regions of Ghana. IJRDO J. Applied Sci., 2016; 2(11): 7-19.
15. Thomachan S., Sindhu S., John V.D. Biochemical activities of Curcuminoid analogues with methyl substituted phenyl ring and their transition metal chelates. IJRDO J. Applied Sci., 2015; 1(8): 33-47.
16. Verdizadeh N.A., Zalov A.Z., Abaskuliyeva U.B., Ephendiyeva N.N., Hasanova N.C. Liquid-liquid extraction and spectrophotometric determination of cromium (VI) with o-hydroxythiophenols in the presence of hydrophobic amines. IJRDO J. Applied Sci., 2017; 3(5): 66-76.
17. Zalov A.Z., Verdizadeh N.A., Aliyev S.G., Mammadova S.A. Extraction and spectropho-tometric determination of tantalum (V) with 2-hydroxythiophenol and its derivatives in the presence of hydrophobic amines. IJRDO J. Applied Sci., 2016; 2(7): 26-37.
18. Verdizade N.A., Kuliev K.A., Alieva K.R. Extractive spectrophotometric determination of iron (III) with 5-(p-hydroxybenzylidene)-thiazolidone-2,4. IJRDO J. Applied Sci., 2016; 2(11): 18-27.
19. Zalov A.Z., Amanullayeva G.I. Spectrophotometric determination of cobalt (II) in a liquid-liquid extraction system containing 2-hydroxy-5-iodothiophenol and diphenylguanidine. IJRDO J. Applied Sci., 2016; 2(7): 17-25.
20. Prasuna N.V., Kumar R.K., Damodharam T. Selective spectrophotometric determination of fluoride in water samples using an Alizarin red S complex as a colored reagent. IJRDO J. Applied Sci., 2015; 1(8): 18-32.
21. Ansari А.M., Kazemipour M., Khosravi F., Baradaran M. A comparative study of first-derivative spectrophotometry and high-performance liquid chromatography applied to the determination of Losartan potassium in tablets. Chem. Pharm. Bull. (Tokyo), 2004; 52(10): 1166-1170.
22. Lastra O.C., Lemus I.G., Sánchez H.J., Pérez R.F. Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets. J. Pharm. Biomed. Anal., 2003; 33(2): 175-180.
23. Si L., Huang J., Gong F., Li G. Pharmacokinetics of Valsartan and Hydrochlorothiazide in healthy volunteers after single administration of its compound dispersible tablets. Zhongguo Yaofang, 2008; 19(29): 2269-2272.
24. Tatar S., Serap S. Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of Valsartan in pharmaceutical formulation. J. Pharm. Biomed. Anal., 2002; 30(2): 371-375.
25. Chitlange S.S., Agarwal B.A., Wankhede S.B., Sakarkar D.M., Padmashri P.D.Y. Spectrophotometric methods for simultaneous determination of Hydrochlorthiazide and valsartan. Asian J. Chem., 2008; 20(4): 2570-2574.
26. Erk N. Spectrophotometric analysis of Valsartan and Hydrochlorothiazide. Anal. Letters, 2002; 35(2): 283-302.
27. Satana E., Altınay S., Göer N.G., Özkan S.A., Sentürk Z. Simultaneous determination of Valsartan and Hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J. Pharm. Biomed. Anal., 2001; 25(5-6): 1009-1013.
28. Stolarczyk M.S., Maslanka A., Krzek J., Milczarek J. Application of derivative spectrophotometry for determination of Enalapril, Hydrochlorothiazide and Valsartan in complex pharmaceutical preparations. Acta Poloniae Pharmaceutica, 2008; 65(3): 275-281.
29. Gupta K.R., Mahapatra A.D., Wadodkar A.R., Wadodkar S.G. Simultaneous UV spectrophotometric determination of Valsartan and Amlodipine in tablet. Int. J. Chem. Tech. Res., 2010; 2(1): 551-556.
30. Sohan S.C., Kiran B., Imran M., Dinesh M.S. Simultaneous spectrophotometric determination of Ramipril and Valsartan in combined dosage form. J. Pharm. Res., 2008; 7(4): 201-203.
31. Tsvetkova D., Obreshkova D., Ivanova St, Yankov V., Atanasov P., Hadjieva B. Telmisartan quality control by validation of UV-spectrophotometric method. Int. J. Innov. Res. Med. Sci., 2016; 1(4 : 113-123.
32. Tsvetkova D.D., Obreshkova D.P. Validation of UV-spectrophotometric method for identification and determination of angiotensin II receptor antagonist Losartan Potassium. Int. J. Pharm. Pharm. Sci., 2012; 4(1): 428-431.
33. Tsvetkova D., Ivanova S. Estimation of validation parameters of UV-spectrophotometric method for analysis of Valsartan. J. Adv. Pharm. Edu. Res., 2018; 8(3): 37-42.
34. International Conference on Harmonization Topic Q 2 (R1). Validation of Analytical Procedures: Text and Methodology. CPMP/ICH/381/95) European Medicines Agency, 1995.
35. Tsvetkova D., Ivanova S. Application of UV-spectrophotometric method for determination of Losartan Potassium in tablets. Indo Amer. J. Pharm, Sci, 2018; 5(8): 8393-8401.
2. Coleman J.J., Butt T.F. Antihypertensive drugs. Side Effects Drugs Annual, 2009; 31(20): 349-370.
3. Ferdinand K.C., Taylor C. The management of hypertension with angiotensin receptor blockers in special populations. Clin. Cornerstone, 2009; 9(Suppl. 3): 5-17.
4. Wachtell K., Lehto M., Gerdts E., Olsen M.H., Hornestam B., Dahlöf B., Ibsen H., Julius S., Kjeldsen S.E., Lindholm L.H., Nieminen M.S., Devereux R.B. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to Atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study. J. Amer. Coll. Cardiol., 2005; 45(5): 712-719.
5. Giles T.D., Oparil S., Silfani T., Walker F. Comparison of ascending doses of Olmesartan medoxomil (O), Losartan potassium (L) and Valsartan (V) in patients (PTS) with essential hypertension (HTN). Amer. J. Hypertens., 2005; 18(5) (Suppl. 1): 59-60.
6. Nixon R.M., Muller E., Lowy A., Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int. J. Clin. Pract., 2009; 63(5): 766-775.
7. Kimura Y., Kitagawa K., Oku N., Kajimoto K., Kato H., Tanaka M., Sakaguchi M., Hougaku H., Sakoda S., Hatazawa J. Blood pressure lowering with Valsartan is associated with maintenance of cerebral blood flow and cerebral perfusion reserve in hypertensive patients with cerebral small vessel disease. J. Stroke Cerebrovasc. Disease, 2010; 19(2): 85-91.
8. Delea T.E., Thomas S.K., Moynihan A., Frech F., Oster G. Valsartan versus Lisinopril or Metoprolol to prevent cardiovascular events in patients with hypertension. Amer. J. Hypertens., 2005; 18(5) (Suppl. 1): 55-56.
9. Solomon S.D., Skali H., Anavekar N.S., Bourgoun M., Barvik S., Ghali J.K., Warnica J.W., Khrakovskaya M., Arnold J.M., Schwartz Y., Velazquez E.J., Califf R.M., McMurray J.V., Pfeffer M.A. Changes in ventricular size and function in patients treated with Valsartan, Captopril, or both after myocardial infarction. Circulation, 2005; 111(25): 3411-3419.
10. Janardhanan R., Daley W.L., Naqvi T.Z., Mulvagh S.L., Aurigemma G., Zile M., Arnold J.M.O., Artis E., Purkayastha S., Thomas J.D., Solomon S.D. Rationale and design: The VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension. Amer. Heart J., 2006; 152(2): 246-252.
11. Solomon S.D.J., Arnold M.O., Aurigemma G.P., Daley W.L., Verma A. The VALIDD study. Lancet, 2007; 370(9591): 931-932.
12. Momoh H., Idris M.M., Adoum O.A. Evaluation of the antimicrobial and cytotoxic effect of Dendranthema indicum (L Desmoul) leave extract. IJRDO J. Applied Sci., 2017; 3(6): 12-19.
13. Momoh H., Dambata, M.B., Tahir M.T. Phytochemical studies, antimicrobial and antituberculosis evaluation of extracts from the stem bark of Psorospermum senegalense (Spach). IJRDO J. Applied Sci., 2017; 3(6): 3-11.
14. Boakye S., Jonfia-Essien W., Voegborlo B.R, Boadi N.O. Assessment of organochlorine pesticides in cocoa beans from Ashanti and Brong Ahafo regions of Ghana. IJRDO J. Applied Sci., 2016; 2(11): 7-19.
15. Thomachan S., Sindhu S., John V.D. Biochemical activities of Curcuminoid analogues with methyl substituted phenyl ring and their transition metal chelates. IJRDO J. Applied Sci., 2015; 1(8): 33-47.
16. Verdizadeh N.A., Zalov A.Z., Abaskuliyeva U.B., Ephendiyeva N.N., Hasanova N.C. Liquid-liquid extraction and spectrophotometric determination of cromium (VI) with o-hydroxythiophenols in the presence of hydrophobic amines. IJRDO J. Applied Sci., 2017; 3(5): 66-76.
17. Zalov A.Z., Verdizadeh N.A., Aliyev S.G., Mammadova S.A. Extraction and spectropho-tometric determination of tantalum (V) with 2-hydroxythiophenol and its derivatives in the presence of hydrophobic amines. IJRDO J. Applied Sci., 2016; 2(7): 26-37.
18. Verdizade N.A., Kuliev K.A., Alieva K.R. Extractive spectrophotometric determination of iron (III) with 5-(p-hydroxybenzylidene)-thiazolidone-2,4. IJRDO J. Applied Sci., 2016; 2(11): 18-27.
19. Zalov A.Z., Amanullayeva G.I. Spectrophotometric determination of cobalt (II) in a liquid-liquid extraction system containing 2-hydroxy-5-iodothiophenol and diphenylguanidine. IJRDO J. Applied Sci., 2016; 2(7): 17-25.
20. Prasuna N.V., Kumar R.K., Damodharam T. Selective spectrophotometric determination of fluoride in water samples using an Alizarin red S complex as a colored reagent. IJRDO J. Applied Sci., 2015; 1(8): 18-32.
21. Ansari А.M., Kazemipour M., Khosravi F., Baradaran M. A comparative study of first-derivative spectrophotometry and high-performance liquid chromatography applied to the determination of Losartan potassium in tablets. Chem. Pharm. Bull. (Tokyo), 2004; 52(10): 1166-1170.
22. Lastra O.C., Lemus I.G., Sánchez H.J., Pérez R.F. Development and validation of an UV derivative spectrophotometric determination of Losartan potassium in tablets. J. Pharm. Biomed. Anal., 2003; 33(2): 175-180.
23. Si L., Huang J., Gong F., Li G. Pharmacokinetics of Valsartan and Hydrochlorothiazide in healthy volunteers after single administration of its compound dispersible tablets. Zhongguo Yaofang, 2008; 19(29): 2269-2272.
24. Tatar S., Serap S. Comparison of UV- and second derivative-spectrophotometric and LC methods for the determination of Valsartan in pharmaceutical formulation. J. Pharm. Biomed. Anal., 2002; 30(2): 371-375.
25. Chitlange S.S., Agarwal B.A., Wankhede S.B., Sakarkar D.M., Padmashri P.D.Y. Spectrophotometric methods for simultaneous determination of Hydrochlorthiazide and valsartan. Asian J. Chem., 2008; 20(4): 2570-2574.
26. Erk N. Spectrophotometric analysis of Valsartan and Hydrochlorothiazide. Anal. Letters, 2002; 35(2): 283-302.
27. Satana E., Altınay S., Göer N.G., Özkan S.A., Sentürk Z. Simultaneous determination of Valsartan and Hydrochlorothiazide in tablets by first-derivative ultraviolet spectrophotometry and LC. J. Pharm. Biomed. Anal., 2001; 25(5-6): 1009-1013.
28. Stolarczyk M.S., Maslanka A., Krzek J., Milczarek J. Application of derivative spectrophotometry for determination of Enalapril, Hydrochlorothiazide and Valsartan in complex pharmaceutical preparations. Acta Poloniae Pharmaceutica, 2008; 65(3): 275-281.
29. Gupta K.R., Mahapatra A.D., Wadodkar A.R., Wadodkar S.G. Simultaneous UV spectrophotometric determination of Valsartan and Amlodipine in tablet. Int. J. Chem. Tech. Res., 2010; 2(1): 551-556.
30. Sohan S.C., Kiran B., Imran M., Dinesh M.S. Simultaneous spectrophotometric determination of Ramipril and Valsartan in combined dosage form. J. Pharm. Res., 2008; 7(4): 201-203.
31. Tsvetkova D., Obreshkova D., Ivanova St, Yankov V., Atanasov P., Hadjieva B. Telmisartan quality control by validation of UV-spectrophotometric method. Int. J. Innov. Res. Med. Sci., 2016; 1(4 : 113-123.
32. Tsvetkova D.D., Obreshkova D.P. Validation of UV-spectrophotometric method for identification and determination of angiotensin II receptor antagonist Losartan Potassium. Int. J. Pharm. Pharm. Sci., 2012; 4(1): 428-431.
33. Tsvetkova D., Ivanova S. Estimation of validation parameters of UV-spectrophotometric method for analysis of Valsartan. J. Adv. Pharm. Edu. Res., 2018; 8(3): 37-42.
34. International Conference on Harmonization Topic Q 2 (R1). Validation of Analytical Procedures: Text and Methodology. CPMP/ICH/381/95) European Medicines Agency, 1995.
35. Tsvetkova D., Ivanova S. Application of UV-spectrophotometric method for determination of Losartan Potassium in tablets. Indo Amer. J. Pharm, Sci, 2018; 5(8): 8393-8401.
Published
2018-09-30
How to Cite
Tsvetkova, D. D., & Ivanova, S. A. (2018). Investigation and estimation of spectrophotometric values specific and molar absorbances for Losartan Potassium and Valsartan. IJRDO-Journal of Applied Science, 4(9), 13-20. https://doi.org/10.53555/as.v4i9.2422
Section
Articles
Copyright (c) 2018 IJRDO - Journal of Applied Science (ISSN: 2455-6653)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Author(s) and co-author(s) jointly and severally represent and warrant that the Article is original with the author(s) and does not infringe any copyright or violate any other right of any third parties, and that the Article has not been published elsewhere. Author(s) agree to the terms that the IJRDO Journal will have the full right to remove the published article on any misconduct found in the published article.
